Literature DB >> 24134304

Hypertension is associated with serologically active disease in patients with systemic lupus erythematosus: role of increased Th1/Th2 ratio and oxidative stress.

M A B Lozovoy1, A N C Simão, H K Morimoto, T M V Iryioda, C Panis, E M V Reiche, S D Borelli, S R Oliveira, R Cecchini, I Dichi.   

Abstract

OBJECTIVES: To determine whether disease activity verified by laboratorial parameters is associated with a higher frequency of hypertension in patients with systemic lupus erythematosus (SLE) without renal impairment and to investigate factors that could influence this hypertension.
METHOD: This study included 102 controls, 70 patients with inactive SLE, and 53 patients with active SLE without renal impairment. We evaluated T helper type 1 (Th1)/Th2 lineage cytokines, nitric oxide (NO), insulin resistance (IR), and oxidative stress.
RESULTS: Patients with active SLE had a higher probability of developing hypertension compared to controls [odds ratio (OR) 3.833, 95% confidence interval (CI) 1.806-8.137, p < 0.0003] and patients with inactive SLE (OR 2.215, 95% CI 1.032-4.752, p = 0.0394). Active SLE patients had a higher interleukin (IL)-12/IL-4 ratio (p < 0.05) than both controls and inactive SLE patients. Protein oxidation was significantly higher in patients with active SLE than in the control group and in patients with inactive SLE (p < 0.01 and p < 0.05, respectively). Multivariate analysis revealed an association between the presence of hypertension and he levels of glucose (p = 0.0276), insulin (p = 0.0498), hydroperoxides (p = 0.0221), IFN-γ (p = 0.0494), IL-17 (p = 0.0272), IL-12/IL-10 (p = 0.0373), IFN-γ/IL-10 (p = 0.0142), IFN-γ/IL-4 (p = 0.0320), and adiponectin (p = 0.0433).
CONCLUSIONS: Patients with active SLE without renal impairment had an increased frequency of high blood pressure (43.4%) compared with patients with inactive SLE (25.7%) and controls (16.7%). Hypertension was associated with serologically active disease and was influenced by an increased Th1/Th2 ratio and oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24134304     DOI: 10.3109/03009742.2013.834963

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  12 in total

1.  Increased lipid and protein oxidation and lowered anti-oxidant defenses in systemic lupus erythematosus are associated with severity of illness, autoimmunity, increased adhesion molecules, and Th1 and Th17 immune shift.

Authors:  Bruna Miglioranza Scavuzzi; Andréa Name Colado Simão; Tatiana Mayumi Veiga Iriyoda; Marcell Alysson Batisti Lozovoy; Nicole Perugini Stadtlober; Lorena Flor da Rosa Franchi Santos; Tamires Flauzino; Fabiano Aparecido de Medeiros; Marcelo Cândido de Sá; Luana Consentin; Edna Maria Vissoci Reiche; Michael Maes; Isaias Dichi
Journal:  Immunol Res       Date:  2018-02       Impact factor: 2.829

Review 2.  The immune system and hypertension.

Authors:  Madhu V Singh; Mark W Chapleau; Sailesh C Harwani; Francois M Abboud
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

Review 3.  Why are kids with lupus at an increased risk of cardiovascular disease?

Authors:  Catherine Quinlan; Stephen D Marks; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2015-09-23       Impact factor: 3.714

4.  NEAT1 regulates Th2 cell development by targeting STAT6 for degradation.

Authors:  Shuman Huang; Dong Dong; Yaqian Zhang; Zhuo Chen; Jing Geng; Yulin Zhao
Journal:  Cell Cycle       Date:  2019-01-17       Impact factor: 4.534

Review 5.  Role of T lymphocytes in hypertension.

Authors:  Jiandong Zhang; Steven D Crowley
Journal:  Curr Opin Pharmacol       Date:  2014-12-15       Impact factor: 5.547

Review 6.  Autoimmune-mediated renal disease and hypertension.

Authors:  Erika I Boesen; Rahul M Kakalij
Journal:  Clin Sci (Lond)       Date:  2021-09-17       Impact factor: 6.876

Review 7.  Influence of treatments on cell adhesion molecules in patients with systemic lupus erythematosus and rheumatoid arthritis: a review.

Authors:  Lorena Flor da Rosa Franchi Santos; Neide Tomimura Costa; Michael Maes; Andréa Name Colado Simão; Isaias Dichi
Journal:  Inflammopharmacology       Date:  2019-12-09       Impact factor: 4.473

8.  Participation of hypertension patients in early-phase clinical trials.

Authors:  Paul Borron; Oren Cohen; Theo J Hoofwijk; J Rick Turner
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-04-22       Impact factor: 3.738

9.  IL-1β and IL-6 Are Highly Expressed in RF+IgE+ Systemic Lupus Erythematous Subtype.

Authors:  Yongkang Wu; Bei Cai; Junlong Zhang; Beilei Shen; Zhuochun Huang; Chunyu Tan; Carla C Baan; Lanlan Wang
Journal:  J Immunol Res       Date:  2017-02-12       Impact factor: 4.818

10.  Single-trait and multi-trait genome-wide association analyses identify novel loci for blood pressure in African-ancestry populations.

Authors:  Jingjing Liang; Thu H Le; Digna R Velez Edwards; Bamidele O Tayo; Kyle J Gaulton; Jennifer A Smith; Yingchang Lu; Richard A Jensen; Guanjie Chen; Lisa R Yanek; Karen Schwander; Salman M Tajuddin; Tamar Sofer; Wonji Kim; James Kayima; Colin A McKenzie; Ervin Fox; Michael A Nalls; J Hunter Young; Yan V Sun; Jacqueline M Lane; Sylvia Cechova; Jie Zhou; Hua Tang; Myriam Fornage; Solomon K Musani; Heming Wang; Juyoung Lee; Adebowale Adeyemo; Albert W Dreisbach; Terrence Forrester; Pei-Lun Chu; Anne Cappola; Michele K Evans; Alanna C Morrison; Lisa W Martin; Kerri L Wiggins; Qin Hui; Wei Zhao; Rebecca D Jackson; Erin B Ware; Jessica D Faul; Alex P Reiner; Michael Bray; Joshua C Denny; Thomas H Mosley; Walter Palmas; Xiuqing Guo; George J Papanicolaou; Alan D Penman; Joseph F Polak; Kenneth Rice; Ken D Taylor; Eric Boerwinkle; Erwin P Bottinger; Kiang Liu; Neil Risch; Steven C Hunt; Charles Kooperberg; Alan B Zonderman; Cathy C Laurie; Diane M Becker; Jianwen Cai; Ruth J F Loos; Bruce M Psaty; David R Weir; Sharon L R Kardia; Donna K Arnett; Sungho Won; Todd L Edwards; Susan Redline; Richard S Cooper; D C Rao; Jerome I Rotter; Charles Rotimi; Daniel Levy; Aravinda Chakravarti; Xiaofeng Zhu; Nora Franceschini
Journal:  PLoS Genet       Date:  2017-05-12       Impact factor: 6.020

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.